Hyaluronan suppresses prostate tumor cell proliferation through diminished expression of N-cadherin and aberrant growth factor receptor signaling

Experimental Cell Research

Volumn 317, Issue 8, 2011, Pages 1214-1225

  Bharadwaj, Alamelu G ^a   Goodrich, Nathaniel P ^a   McAtee, Caitlin O ^a   Haferbier, Katie ^a   Oakley, Gregory G ^a   Wahl, James K ^b   Simpson, Melanie A ^a,c  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cadherin; Cell adhesion; Cell cycle; Hyaluronan; Integrin; Prostate cancer

Indexed keywords

BETA CATENIN; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN D; GROWTH FACTOR RECEPTOR; HYALURONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PROTEIN P21; PROTEIN P27; TUBULIN; UVOMORULIN;

ARTICLE; CELL ADHESION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SYNCHRONIZATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 79953104675     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.01.026     Document Type: Article

References (65)

1. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4:528-539.
2. Auvinen P., Tammi R., Parkkinen J., Tammi M., Agren U., Johansson R., Hirvikoski P., Eskelinen M., Kosma V.M. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 2000, 156:529-536.
3. Ropponen K., Tammi M., Parkkinen J., Eskelinen M., Tammi R., Lipponen P., Agren U., Alhava E., Kosma V.M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 1998, 58:342-347.
4. M.W. Kramer, D.O. Escudero, S.D. Lokeshwar, R. Golshani, O.O. Ekwenna, K. Acosta, A.S. Mersegurger, M. Soloway, V.B. Lokeshwar, Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis, Cancer.
5. Lokeshwar V.B., Rubinowicz D., Schroeder G.L., Forgacs E., Minna J.D., Block N.L., Nadji M., Lokeshwar B.L. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J. Biol. Chem. 2001, 276:11922-11932.
6. Bharadwaj A.G., Kovar J.L., Loughman E., Elowsky C., Oakley G.G., Simpson M.A. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am. J. Pathol. 2009, 174:1027-1036.
7. Udabage L., Brownlee G.R., Nilsson S.K., Brown T.J. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp. Cell Res. 2005, 310:205-217.
8. Udabage L., Brownlee G.R., Waltham M., Blick T., Walker E.C., Heldin P., Nilsson S.K., Thompson E.W., Brown T.J. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res. 2005, 65:6139-6150.
9. Ekici S., Cerwinka W.H., Duncan R., Gomez P., Civantos F., Soloway M.S., Lokeshwar V.B. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int. J. Cancer 2004, 112:121-129.
10. Posey J.T., Soloway M.S., Ekici S., Sofer M., Civantos F., Duncan R.C., Lokeshwar V.B. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res. 2003, 63:2638-2644.
11. Weigel P.H., Hascall V.C., Tammi M. Hyaluronan synthases. J. Biol. Chem. 1997, 272:13997-14000.
12. Itano N., Sawai T., Atsumi F., Miyaishi O., Taniguchi S., Kannagi R., Hamaguchi M., Kimata K. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J. Biol. Chem. 2004, 279:18679-18687.
13. Lokeshwar V.B., Cerwinka W.H., Isoyama T., Lokeshwar B.L. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res. 2005, 65:7782-7789.
14. Pardee A.B. A restriction point for control of normal animal cell proliferation. Proc. Natl Acad. Sci. USA 1974, 71:1286-1290.
15. Schwartz M.A., Assoian R.K. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J. Cell Sci. 2001, 114:2553-2560.
16. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
17. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80:179-185.
18. Bottazzi M.E., Zhu X., Bohmer R.M., Assoian R.K. Regulation of p21(cip1) expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase. J. Cell Biol. 1999, 146:1255-1264.
19. Roovers K., Assoian R.K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000, 22:818-826.
20. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995, 9:1149-1163.
21. Torii S., Yamamoto T., Tsuchiya Y., Nishida E. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 2006, 97:697-702.
22. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr. Opin. Cell Biol. 2001, 13:555-562.
23. Kim J.H., Kushiro K., Graham N.A., Asthagiri A.R. Tunable interplay between epidermal growth factor and cell-cell contact governs the spatial dynamics of epithelial growth. Proc. Natl Acad. Sci. USA 2009, 106:11149-11153.
24. Bharadwaj A.G., Rector K., Simpson M.A. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis. J. Biol. Chem. 2007, 282:20561-20572.
25. Simpson M.A. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am. J. Pathol. 2006, 169:247-257.
26. Murphy L.O., Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem. Sci. 2006, 31:268-275.
27. Balmanno K., Cook S.J. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999, 18:3085-3097.
28. Lavoie J.N., L'Allemain G., Brunet A., Muller R., Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 1996, 271:20608-20616.
29. Murphy L.O., Smith S., Chen R.H., Fingar D.C., Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 2002, 4:556-564.
30. Weber J.D., Raben D.M., Phillips P.J., Baldassare J.J. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 1997, 326(Pt 1):61-68.
31. Fournier A.K., Campbell L.E., Castagnino P., Liu W.F., Chung B.M., Weaver V.M., Chen C.S., Assoian R.K. Rac-dependent cyclin D1 gene expression regulated by cadherin- and integrin-mediated adhesion. J. Cell Sci. 2008, 121:226-233.
32. Klein E.A., Campbell L.E., Kothapalli D., Fournier A.K., Assoian R.K. Joint requirement for Rac and ERK activities underlies the mid-G1 phase induction of cyclin D1 and S phase entry in both epithelial and mesenchymal cells. J. Biol. Chem. 2008, 283:30911-30918.
33. Won K.A., Xiong Y., Beach D., Gilman M.Z. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc. Natl Acad. Sci. USA 1992, 89:9910-9914.
34. Lieu C.H., Liu C.C., Yu T.H., Chen K.D., Chang Y.N., Lai Y.K. Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ. 1998, 9:767-776.
35. Shin H.J., Baek K.H., Jeon A.H., Kim S.J., Jang K.L., Sung Y.C., Kim C.M., Lee C.W. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 2003, 22:3853-3858.
36. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88:2619-2628.
37. Wheelock M.J., Johnson K.R. Cadherin-mediated cellular signaling. Curr. Opin. Cell Biol. 2003, 15:509-514.
38. Kothapalli D., Flowers J., Xu T., Pure E., Assoian R.K. Differential activation of ERK and Rac mediates the proliferative and anti-proliferative effects of hyaluronan and CD44. J. Biol. Chem. 2008, 283:31823-31829.
39. Misra S., Toole B.P., Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem. 2006, 281:34936-34941.
40. Kothapalli D., Zhao L., Hawthorne E.A., Cheng Y., Lee E., Pure E., Assoian R.K. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J. Cell Biol. 2007, 176:535-544.
41. Han E.K., Lim J.T., Arber N., Rubin M.A., Xing W.Q., Weinstein I.B. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998, 35:95-101.
42. Gregory C.W., Johnson R.T., Presnell S.C., Mohler J.L., French F.S. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J. Androl. 2001, 22:537-548.
43. Hayashi H., Matsuzaki O., Muramatsu S., Tsuchiya Y., Harada T., Suzuki Y., Sugano S., Matsuda A., Nishida E. Centaurin-alpha1 is a phosphatidylinositol 3-kinase-dependent activator of ERK1/2 mitogen-activated protein kinases. J. Biol. Chem. 2006, 281:1332-1337.
44. Hulleman E., Boonstra J. Regulation of G1 phase progression by growth factors and the extracellular matrix. Cell. Mol. Life Sci. 2001, 58:80-93.
45. El Sheikh S.S., Domin J., Abel P., Stamp G., Lalani N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004, 6:846-853.
46. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 2008, 14:159-169.
47. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
48. Gartel A.L. Is p21 an oncogene?. Mol. Cancer Ther. 2006, 5:1385-1386.
49. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11:847-862.
50. Roninson I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002, 179:1-14.
51. Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995, 375:159-161.
52. Cuff C.A., Kothapalli D., Azonobi I., Chun S., Zhang Y., Belkin R., Yeh C., Secreto A., Assoian R.K., Rader D.J., Pure E. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J. Clin. Invest. 2001, 108:1031-1040.
53. Ghatak S., Misra S., Toole B.P. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J. Biol. Chem. 2005, 280:8875-8883.
54. Legg J.W., Lewis C.A., Parsons M., Ng T., Isacke C.M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat. Cell Biol. 2002, 4:399-407.
55. Morrison H., Sherman L.S., Legg J., Banine F., Isacke C., Haipek C.A., Gutmann D.H., Ponta H., Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001, 15:968-980.
56. Kovar J.L., Johnson M.A., Volcheck W.M., Chen J., Simpson M.A. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am. J. Pathol. 2006, 169:1415-1426.
57. Wheelock M.J., Shintani Y., Maeda M., Fukumoto Y., Johnson K.R. Cadherin switching. J. Cell Sci. 2008, 121:727-735.
58. De Bruin A., Muller E., Wurm S., Caldelari R., Wyder M., Wheelock M.J., Suter M.M. Loss of invasiveness in squamous cell carcinoma cells overexpressing desmosomal cadherins. Cell Adhes. Commun. 1999, 7:13-28.
59. Ewing C.M., Ru N., Morton R.A., Robinson J.C., Wheelock M.J., Johnson K.R., Barrett J.C., Isaacs W.B. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res. 1995, 55:4813-4817.
60. Maeda M., Johnson E., Mandal S.H., Lawson K.R., Keim S.A., Svoboda R.A., Caplan S., Wahl J.K., Wheelock M.J., Johnson K.R. Expression of inappropriate cadherins by epithelial tumor cells promotes endocytosis and degradation of E-cadherin via competition for p120(ctn). Oncogene 2006, 25:4595-4604.
61. Jaggi M., Nazemi T., Abrahams N.A., Baker J.J., Galich A., Smith L.M., Balaji K.C. N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate 2006, 66:193-199.
62. Tomita K., van Bokhoven A., van Leenders G.J., Ruijter E.T., Jansen C.F., Bussemakers M.J., Schalken J.A. Cadherin switching in human prostate cancer progression. Cancer Res. 2000, 60:3650-3654.
63. Perrais M., Chen X., Perez-Moreno M., Gumbiner B.M. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol. Biol. Cell 2007, 18:2013-2025.
64. Qian X., Karpova T., Sheppard A.M., McNally J., Lowy D.R. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004, 23:1739-1748.
65. Tanaka H., Kono E., Tran C.P., Miyazaki H., Yamashiro J., Shimomura T., Fazli L., Wada R., Huang J., Vessella R.L., An J., Horvath S., Gleave M., Rettig M.B., Wainberg Z.A., Reiter R.E. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 2011, 16:1414-1420.